Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer

被引:43
|
作者
Honselmann, Kim C. [1 ,2 ,3 ]
Pergolini, Ilaria [1 ,2 ]
Fernandez-del Castillo, Carlos [1 ,2 ]
Deshpande, Vikram [1 ,2 ]
Ting, David [2 ,4 ]
Taylor, Martin S. [1 ,2 ]
Bolm, Louisa [3 ]
Qadan, Motaz [1 ,2 ]
Wellner, Ulrich [3 ]
Sandini, Marta [1 ,2 ]
Bausch, Dirk [3 ]
Warshaw, Andrew L. [1 ,2 ]
Lillemoe, Keith D. [1 ,2 ]
Keck, Tobias [3 ]
Ferrone, Cristina R. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Dept Gastrointestinal Surg & Pathol, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Med Ctr Schleswig Holstein, Dept Surg, Campus Luebeck, Lubeck, Germany
[4] Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02114 USA
关键词
lymph node status; PDAC; recurrence; survival; SHORT-COURSE CHEMORADIATION; PROTON-BEAM THERAPY; LONG-TERM SURVIVAL; DUCTAL ADENOCARCINOMA; NEOADJUVANT TREATMENT; PANCREATICODUODENECTOMY; CAPECITABINE;
D O I
10.1097/SLA.0000000000003123
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: Our aim was to evaluate recurrence patterns of surgically resected PDAC patients with negative (pN0) or positive (pN1) lymph nodes. Summary Background Data: Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer death by 2030. This is mostly due to early local and distant metastasis, even after surgical resection. Knowledge about patterns of recurrence in different patient populations could offer new therapeutic avenues. Methods: Clinicopathologic data were collected for 546 patients who underwent resection of their PDAC between 2005 and 2016 from 2 tertiary university centers. Patients were divided into an upfront resection group (n = 394) and a neoadjuvant group (n = 152). Results: Tumor recurrence was significantly less common in pN0 patients as compared with pN1 patients, (upfront surgery: 55% vs. 77%,P< 0.001 and 64% vs. 78%,P= 0.040 in the neoadjuvant group). In addition, time to recurrence was significantly longer in pN0 versus pN1 patients in the upfront resected patients (median 16 mo pN0 vs. 10 mo pN1P< 0.001), and the neoadjuvant group (pN0 21 mo vs. 11 mo pN1,P< 0.001). Of the patients who recurred, 62% presented with distant metastases (63% of pN0 and 62% of pN1,P= 0.553), 24% with local disease (27% of pN0 and 23% of pN1,P= 0.672) and 14% with synchronous local and distant disease (10% of pN0 and 15% of pN1,P= 0.292). Similarly, there was no difference in recurrence patterns between pN0 and pN1 in the neoadjuvant group, in which 68% recurred with distant metastases (76% of pN0 and 64% of pN1,P= 0.326) and 18% recurred with local disease (pN0: 22% and pN1: 15%,P= 0.435). Conclusion: Time to recurrence was significantly longer for pN0 patients. However, patterns of recurrence for pN0 vs. pN1 patients were identical. Lymph node status was predictive of time to recurrence, but not location of recurrence.
引用
收藏
页码:357 / 365
页数:9
相关论文
共 50 条
  • [41] Node-Negative Versus Node-Positive Papillary Thyroid Carcinoma: A Comparison of Clinicopathologic and Molecular Findings
    Kotliar, Justin A.
    Kragel, Peter
    LABORATORY INVESTIGATION, 2016, 96 : 149A - 150A
  • [42] Node-Negative Versus Node-Positive Papillary Thyroid Carcinoma: A Comparison of Clinicopathologic and Molecular Findings
    Kothar, Justin A.
    Kragel, Peter
    MODERN PATHOLOGY, 2016, 29 : 149A - 150A
  • [43] Factors associated with receipt of adjuvant radioactive iodine in node-negative versus node-positive papillary thyroid cancer.
    Chagpar, Ryaz
    Berber, Eren
    Mitchell, Jamie
    Shin, Joyce
    Jin, Judy
    Metzger, Rosemarie
    Siperstein, Allan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Lymphovascular Invasion (LVI) and Overall Survival in Node-negative and Node-positive Breast Cancer Patients: A Meta-analysis.
    Sahebjam, S.
    Diaz-Padilla, I.
    Ocana, A.
    Seruga, B.
    Amir, E.
    CANCER RESEARCH, 2012, 72
  • [45] Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients
    Pierce, Aisling
    Saldova, Radka
    Abd Hamid, Umi M.
    Abrahams, Jodie L.
    McDermott, Enda W.
    Evoy, Denis
    Duffy, Michael J.
    Rudd, Pauline M.
    GLYCOBIOLOGY, 2010, 20 (10) : 1283 - 1288
  • [46] Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
    Poorvu, Philip D.
    Gelber, Shari, I
    Rosenberg, Shoshana M.
    Ruddy, Kathryn J.
    Tamimi, Rulla M.
    Collins, Laura C.
    Peppercorn, Jeffrey
    Schapira, Lidia
    Borges, Virginia F.
    Come, Steven E.
    Warner, Ellen
    Jakubowski, Debbie M.
    Russell, Christy
    Winer, Eric P.
    Partridge, Ann H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (07) : 725 - +
  • [47] MUTATIONS IN RESECTED NODE-NEGATIVE LUNG ADENOCARCINOMA
    Yip, P. Y.
    Yu, B.
    Cooper, W. A.
    Kench, J. G.
    Boyer, M.
    Kohonen-Corish, M. J.
    Trent, R.
    McCaughan, B.
    Kennedy, C.
    O'Toole, S. A.
    Horvath, L.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S189 - S190
  • [48] Clinical Implication of Node-negative Resectable Pancreatic Cancer
    Yamada, Mihoko
    Sugiura, Teiichi
    Okamura, Yukiyasu
    Ito, Takaaki
    Yamamoto, Yusuke
    Ashida, Ryo
    Ohgi, Katsuhisa
    Aramaki, Takeshi
    Endo, Masahiro
    Uesaka, Katsuhiko
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (04) : 2257 - 2264
  • [49] Clinical Implication of Node-negative Resectable Pancreatic Cancer
    Mihoko Yamada
    Teiichi Sugiura
    Yukiyasu Okamura
    Takaaki Ito
    Yusuke Yamamoto
    Ryo Ashida
    Katsuhisa Ohgi
    Takeshi Aramaki
    Masahiro Endo
    Katsuhiko Uesaka
    Annals of Surgical Oncology, 2021, 28 : 2257 - 2264
  • [50] Node-Negative Disease in Pancreatic Cancer Might Not Present Different Tumor Biology
    Honselmann, K. C.
    Pergolini, I.
    Fernandez-Del Castillo, C.
    Warshaw, A. L.
    Lillemoe, K. D.
    Ferrone, C. R.
    PANCREAS, 2016, 45 (10) : 1511 - 1511